( en | de | ru )

 

Disambiguierung von "Hasenclever, Dirk"

Autor der Publikation

KopierenLöschenDiese Publikation zur Ablage hinzufügen
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

, , , , , , , , , , , , , , , und . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 (3): 818–829 (1998)

Bitte wählen Sie eine Person um die Publikation zuzuordnen

Um zwischen Personen mit demselben Namen zu unterscheiden, wird der akademische Grad und der Titel einer wichtigen Publikation angezeigt. Zudem lassen sich über den Button neben dem Namen einige der Person bereits zugeordnete Publikationen anzeigen.

Dirk Hasenclever

Hertha Hasenclever

Max Hasenclever

Christa Hasenclever

Catharina Hasenclever

 

Weitere Publikationen von Autoren mit dem selben Namen

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease, und . The New England journal of medicine, 339 (21): 1506–1514 (1998)Regression with bounded outcome score: evaluation of power by bootstrap and simulation in a chronic myelogenous leukaemia clinical trial, , und . Statistics in medicine, 17 (17): 1909–1922 (1998)Development and implementation of an analysis tool for array-based comparative genomic hybridization, , , , , , und . Methods of information in medicine, 46 (5): 608–613 (2007)Dose escalation of cytotoxic drugs using haematopoietic growth factors: a randomized trial to determine the magnitude of increase provided by GM-CSF, , , , , , , , , und 3 andere Autor(en). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 12 (4): 471–477 (2001)Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence, , und . Antiviral therapy, 13 (2): 211–220 (2008)Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group, , , , , , , , , und . Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 (3): 580–586 (1994)The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies, , , , , , , , , und 7 andere Autor(en). Klinische Pädiatrie, 216 (3): 150–156 (2004)Are endoscopic antireflux therapies cost-effective compared with laparoscopic fundoplication?, , , , , , und . Endoscopy, 37 (3): 217–222 (2005)The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis, , , , , , , , , und 1 andere Autor(en). Thrombosis and haemostasis, 99 (5): 925–929 (2008)Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL, , , , , , , , , und 3 andere Autor(en). Blood, 104 (3): 634–641 (2004)